Accessibility Statement Skip Navigation
  • Back to Global Sites
  • +971 (0) 4 368 1644
  • GDPR
  • Journalists
  • Send a Release
PR Newswire: news distribution, targeting and monitoring
  • News
  • Products
  • Contact
  • Hamburger menu
  • PR Newswire: news distribution, targeting and monitoring
  • Send a Release
    • Telephone

    • +971 (0) 4 368 1644 from 8 AM - 5:30 PM GMT

    • Contact
    • Contact

      +971 (0) 4 368 1644
      from 8 AM - 5:30 PM GMT

  • Request More Information
  • Journalists
  • GDPR
  • Request More Information
  • Journalists
  • GDPR
  • Request More Information
  • Journalists
  • GDPR
  • Request More Information
  • Journalists
  • GDPR

MAYPHARM CO., LTD. Launches SKINCOLLA: The World's First Recombinant Human Collagen Filler for Superior Skin Rejuvenation
  • USA - Deutsch
  • Россия - Pусский
  • MEXICO - Spanish
  • BRAZIL - Portuguese
  • USA - Français
  • USA - español
  • Middle East - Arabic


News provided by

Maypharm

14 Feb, 2025, 08:38 GMT

Share this article

Share toX

Share this article

Share toX

Groundbreaking Technology Combines Recombinant Human Collagen and Hyaluronic Acid for Immediate, Long-Lasting Results

SEOUL, South Korea, Feb. 14, 2025 /PRNewswire/ -- MAYPHARM CO., LTD. proudly introduces SKINCOLLA, the world's first recombinant human collagen filler, marking a significant breakthrough in skin rejuvenation technology. Utilizing Demulcent™ Type I recombinant collagen, SKINCOLLA offers natural solution for achieving youthful, revitalized skin.

Revolutionizing Collagen Filler Technology

Continue Reading
MAYPHARM CO., LTD. Launches SKINCOLLA: The World’s First Recombinant Human Collagen Filler for Superior Skin Rejuvenation
MAYPHARM CO., LTD. Launches SKINCOLLA: The World’s First Recombinant Human Collagen Filler for Superior Skin Rejuvenation

SKINCOLLA is a game-changer in aesthetic treatments. It combines 100% human-identical recombinant collagen with Hyaluronic Acid (HA), providing immediate and lasting improvements to skin texture, elasticity, and hydration. This cutting-edge formula mimics the body's natural collagen, restoring firmness, smoothness, and addressing common signs of aging such as wrinkles, sagging, and volume loss.

Why Recombinant Human Collagen?

Highly Body-Friendly: SKINCOLLA's recombinant collagen is genetically identical to human collagen, ensuring superior biocompatibility and minimizing the risk of allergic reactions.

With no synthetic additives, SKINCOLLA ensures optimal rejuvenation, making it a reliable choice for skin enhancement.

Minimal Pain and No Downtime: Thanks to its structural similarity to natural collagen, SKINCOLLA injections are less painful, and the treatment involves no downtime, allowing patients to return to their daily activities immediately.

Cultural Sensitivity: SKINCOLLA is designed with respect to diverse cultural and religious preferences, ensuring it's suitable for patients from all backgrounds, including those adhering to Islamic guidelines.

Cutting-Edge Technology for Long-Lasting Results

The proprietary Demulcent™ Type I recombinant collagen in SKINCOLLA is produced in a controlled, high-tech environment. The inclusion of 50mg of HA in the formula further enhances hydration, providing a dual-action solution that amplifies the rejuvenating effects.

Who Can Benefit from SKINCOLLA?

SKINCOLLA is ideal for individuals seeking:

Natural, subtle results without the "overdone" look often associated with traditional fillers.

Non-invasive skin rejuvenation to improve elasticity, firmness, and hydration.

Long-term anti-aging benefits, boosting collagen production for sustained skin improvement.

Indications for SKINCOLLA

Facial Wrinkles: Neck wrinkles, nasolabial folds, forehead lines, crow's feet, and marionette lines.

Eyes: Dark circle reduction, eye wrinkles, and puffiness.

Body: Skin tightening and brightening in areas such as hands, knees, elbows, and armpits.

For more information about SKINCOLLA and other products from MAYPHARM CO., LTD., please visit www.maypharm.net or contact [email protected].

Photo - https://mma.prnewswire.com/media/2620398/MAYPHARM_CO_LTD_Launches_SKINCOLLA_The_World_s_First_Recombinant_Human.jpg

Modal title

Also from this source

Maypharm Unveils Revolutionary Hybrid Filler, Hyalmass Aqua-Exosome: The Future of Skin Hydration and Regeneration

Maypharm Unveils Revolutionary Hybrid Filler, Hyalmass Aqua-Exosome: The Future of Skin Hydration and Regeneration

Maypharm Co., Ltd., a leading innovator in medical and dermo-cosmetic products, proudly introduces the global launch of Hyalmass Aqua-Exosome, a...

المزيد من الإصدارات من هذا المصدر

Explore

Cosmetics and Personal Care

Cosmetics and Personal Care

Household, Consumer & Cosmetics

Household, Consumer & Cosmetics

Biotechnology

Biotechnology

Health Care & Hospitals

Health Care & Hospitals

المزيد من البيانات الصحفية في مواضيع ذات صلة

Contact PR Newswire

  • +971 (0) 4 368 1644
    from 8 AM - 5:30 PM GMT

Global Sites

  • APAC
  • APAC - Traditional Chinese
  • Asia
  • Brazil
  • Canada
  • Czech
  • Denmark
  • Finland
  • France
  • Germany

 

  • India
  • Indonesia
  • Israel
  • Italy
  • Mexico
  • Middle East
  • Middle East - Arabic
  • Netherlands
  • Norway
  • Poland

 

  • Portugal
  • Russia
  • Slovakia
  • Spain
  • Sweden
  • United Kingdom
  • United States

Do not sell or share my personal information:

  • Submit via [email protected] 
  • Call Privacy toll-free: 877-297-8921
Global Sites
  • Asia
  • Brazil
  • Canada
  • Czech
  • Denmark
  • Finland
  • France
  • Germany
  • India
  • Israel
  • Italy
  • Mexico
  • Middle East
  • Netherlands
  • Norway
  • Poland
  • Portugal
  • Russia
  • Slovakia
  • Spain
  • Sweden
  • United Kingdom
  • United States
+971 (0) 4 368 1644
from 8 AM - 5:30 PM GMT
  • Terms of Use
  • Privacy Policy
  • Information Security Policy
  • Site Map
  • Cookie Settings
Copyright © 2025 Cision US Inc.